Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
- Status
- TERMINATED
- Phase
- PHASE3
Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE4
Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)
- Status
- COMPLETED
- Phase
- PHASE2
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2